Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U. Gebrael G, et al. Among authors: srivastava a. Cancer. 2024 Aug 1;130(15):2621-2628. doi: 10.1002/cncr.35302. Epub 2024 Apr 2. Cancer. 2024. PMID: 38564301
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: srivastava a. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):279-282. doi: 10.1038/s41391-023-00696-w. Epub 2023 Jul 17. Prostate Cancer Prostatic Dis. 2024. PMID: 37460732
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: srivastava a. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):357. doi: 10.1038/s41391-023-00706-x. Prostate Cancer Prostatic Dis. 2024. PMID: 37620429 No abstract available.
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: srivastava a. Prostate. 2024 Jun;84(9):888-892. doi: 10.1002/pros.24696. Epub 2024 Apr 1. Prostate. 2024. PMID: 38561317
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy.
Mathew Thomas V, Sayegh N, Chigarira B, Gebrael G, Tripathi N, Nussenzveig R, Jo Y, Dal E, Galarza Fortuna G, Li H, Sahu KK, Srivastava A, Maughan BL, Agarwal N, Swami U. Mathew Thomas V, et al. Among authors: srivastava a. Eur Urol Oncol. 2024 Dec;7(6):1462-1468. doi: 10.1016/j.euo.2024.04.013. Epub 2024 May 11. Eur Urol Oncol. 2024. PMID: 38735779
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations.
Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U. Narang A, et al. Among authors: srivastava a. Kidney Cancer. 2024 Sep 5;8(1):135-142. doi: 10.3233/KCA-240016. eCollection 2024. Kidney Cancer. 2024. PMID: 39263256 Free PMC article.
7,421 results